The move, it said, will enhance PPD’s ability to meet growing customer demand in Europe, the Middle East and Africa (EMEA), and the Asia-Pacific (APAC) region for scientific and technical expertise – by offering these services at the Athlone operation, the CRO said it can provide clients in these locations with the same services already available in the US.
Christopher Fikry, executive vice president, PPD Laboratories, said: “The expansion of our Athlone GMP laboratory represents PPD’s ongoing investment toward continued growth of our operations in Ireland in order to offer enhanced service capabilities to our growing client base in that region and throughout the world.”
Weighing in on the new CGT testing capabilities the Irish site will provide, he told BioPharma-Reporter: “Cell and gene therapy products are next generation pharmaceuticals that offer novel technologies for new options for treating diseases. Where no treatment or cure is available these products have the potential for opening new doors for drug development. PPD’s GMP lab in Middleton, Wisconsin, US, is already working on this extremely exciting and pioneering field, so we are incorporating this same knowledge into the operations of our GMP Lab in Athlone.”
The Athlone operations, added Fikry, have seen significant growth in recent years due to the need for biopharmaceutical testing related to late-stage clinical and commercial programs. The site offers analytical services across all phases of pharmaceutical development and commercialization, with the idea of of helping customers fulfill regulatory requirements for release testing and qualified person (QP) services for clinical and marketed pharmaceuticals in the EU, including small and large molecules and inhaled products.